Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of DRL-17822 in Type II Hyperlipidemia
NCT01388816Phase 2Completed
- Sponsor
- Dr. Reddy's Laboratories
- Start
- Jul 2011
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of DRL-17822 in type 2 hyperlipidemia (4 arms), sponsored by Dr. Reddy's Laboratories. Primary endpoint: Percent Change in HDL-C From Baseline at 28 days. Started Jul 2011; status: completed.
02
Drugs
DRL-17822
03
Conditions
type 2 hyperlipidemia
Beyond the preview
Go deeper on NCT01388816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01388816.